Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Research Council grant · Running

Custom-Made Custom-made Neurons for Cell Therapy in Parkinson’s and Huntington’s Disease

Coordinator
Universita Degli Studi Di Milano, Italy
Runs
1 November 2025 to 31 October 2031
Status
Running
EU funding
€10.0m
Total cost
€10.0m
Partners
4 organisations in 3 countries
Type
European Research Council grant
Grant agreement
101167102

What the project is doing

In the project's own words, from its summary on CORDIS.

The rising incidence of age-associated neurodegenerative diseases, due to increased life expectancy, poses a challenge to the brain's limited regenerative capabilities. Stem cell-based therapies offer promise for addressing crucial neuron loss, particularly in Parkinson’s and Huntington’s diseases (PD and HD). Ongoing first-generation stem cell trials, replacing damaged neurons with healthy ones, represent a notable advancement.

However, their impact is constrained by a ‘one-cell-fits-all’ generic therapy that does not take in account the diverse clinical needs due to variations in disease etiology, stage, patient heterogeneity, and daily fluctuations in graft requirements. CUSTOM-MADE is a transformative initiative advancing knowledge and crafting a tailored portfolio of stem cell products for individual patients or patient subgroups, notably targeting PD and HD.

Integrating stem cell technologies, genomics and bioengineering, CUSTOM-MADE develops rational graft composites of therapeutic neurons and complementary cells to meet the clinical needs of individual patients. Moving into preclinical animal models, the project refines graft connectivity and functional recovery post-transplantation. A groundbreaking leap involves modeling circuitry reconstruction in a fully humanized 3D in-vitro bioengineered system - the connectoids, allowing detailed studies at cellular and molecular levels for defining factors controlling correct and functional graft integration.

For increased translatability, CUSTOM-MADE pioneers the generation of cell products whose activity can be self-regulated or tuned to the patients’ individual requirements. The project implements strategic measures to shield grafts from pathology and introduces the innovative concept of grafted cells exhibiting disease-modifying activity. In essence, CUSTOM-MADE drives the field toward customized stem-cell therapies for PD and HD, marking a paradigm shift in the treatment landscape of neurodegenerative diseases.

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Di MilanoMilanoItalyCoordinator
Danmarks Tekniske UniversitetKongens LyngbyDenmarkParticipant
Universita Degli Studi Di TorinoTorinoItalyParticipant
Lunds UniversitetLundSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI